[Multiple endocrine neoplasia type 1: recent developments and guidelines for DNA diagnosis and periodic clinical monitoring].
Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominantly inherited disorder, characterised by the occurrence of multiple tumours, particularly in the parathyroid glands, the pancreatic islets, the pituitary gland, the adrenal glands, as well as neuroendocrine carcinoid tumours. Since the identification of the responsible gene in 1997, the diagnosis MEN-1 can be assessed easily, and even presymptomatically, by DNA analysis. An early diagnosis is of importance because through periodic clinical monitoring of (putative) MEN1 gene germline mutation carriers, tumour development can be detected and treated at an early stage. Eligible for DNA analysis are MEN-1 patients and their family members, as well as patients with seemingly sporadic MEN-1 related tumours in whom on clinical grounds carriership of a MEN1 gene germline mutation is suspected. Eligible for periodic clinical monitoring are putative and confirmed carriers of a MEN1 germline mutation from the age of 5.
Dreijerink
K M
KM
Divisie Inwendige Geneeskunde en Dermatologie, afd. Endocrinologie, Universitair Medisch Centrum, Postbus 85.500, 3508 GA Utrecht.
Roijers
J F
JF
van der Luijt
R B
RB
Höppener
J W
JW
Lips
C J
CJ
D000328:Adult; D002648:Child; D004252:DNA Mutational Analysis / Q000379:methods*; D003937:Diagnosis, Differential; D006580:Genetic Carrier Screening / Q000379:methods; D005820:Genetic Testing / Q000379:methods; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D018761:Multiple Endocrine Neoplasia Type 1 / Q000175:diagnosis* / Q000235:genetics*; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis* / Q000235:genetics; D009426:Netherlands; D018579:Patient Selection; D017410:Practice Guidelines as Topic